Infectious Diseases Working Party (IDWP)
Transplant Complications Working Party (TCWP)
Study type:
Study number:
2013-003831-31
Type of treatment:
Diseases:
Complications: infectious
Short title:
MK8228
Primary objective:
To evaluate the efficacy of MK-8228 in the prevention of clinically significant CMV infection through Week 24 (~6 months) post-transplant following administration of MK-8228 or placebo.
Key inclusion criteria:
Country:
Austria
Belgium
Brazil
Canada
Finland
France
Germany
Italy
Japan
Lithuania
New Zealand
Peru
Poland
Romania
South Korea
Spain
Sweden
Turkey
United Kingdom
United States
Principal investigator:
EBMT Study coordinator:
Sue Philpott